Flex Pharma Initiates CMT Phase 2 Trial with FLX-787 in US
Flex Pharma announced that, under its open investigational new drug (IND) application, the Company has initiated a Phase 2 randomized, controlled, double-blinded, parallel design trial…
Read More...
Read More...
